Press releases
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
More ▼
Key statistics
As of last trade Actinium Pharmaceuticals Inc (7AY1:FRA) traded at 6.71, -22.66% below its 52-week high of 8.67, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.71 |
---|---|
High | 6.71 |
Low | 6.71 |
Bid | 6.89 |
Offer | 7.00 |
Previous close | 7.19 |
Average volume | 1.07k |
---|---|
Shares outstanding | 29.40m |
Free float | 28.76m |
P/E (TTM) | -- |
Market cap | 213.12m USD |
EPS (TTM) | -1.84 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 07:01 BST.
More ▼